Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 25 versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 25 versus WESTADONE.
FENTANYL-25 vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia by activating G-protein coupled opioid receptors in the CNS, leading to decreased neurotransmitter release and hyperpolarization of neurons.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
25 mcg/h transdermal patch applied every 72 hours; for opioid-tolerant patients only.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 3-12 hours in elderly, hepatic impairment, or critical illness; context: duration of action shorter due to redistribution.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Renal (75% as metabolites, <10% unchanged); Fecal (9%); Biliary (minor).
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist